top of page
MiniBinders: A novel approach to extracellular protein degradation
We have identified a novel modality that is well-suited for targeted protein degradation.
We have identified and characterized E3 ligases expressed on cancer cells, opening up the door to new targets and indications.
CargoTek: Re-doseable AAV therapies
Demonstrated re-dosing of AAV in mice with CargoTek.
Entered into a strategic research collaboration with AAV company.
StressTek: rHSPB5 treatment for autoimmune disorders
Unconventional use of rHSPB5 as a therapeutic.
Acquired rights to DC-TAB, previously in the clinic for MS, in 2020.
Demonstrated POC studies in 2021-2022.
bottom of page